



**Pfizer Limited**

The Capital, 1802 / 1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

May 13, 2016

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai - 400 001

The Manager  
Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051

Dear Sirs,

**Sub: Sale of Four Products to Piramal Enterprises Limited**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has entered into an agreement with Piramal Enterprises Limited for sale of its 4 products viz., Neko Soap, Sloans, Ferradol and Waterbury's Compound for a total consideration of Rs. 110 Crores, subject to adjustments for inventory on closing and transaction costs.

The Press note issued in this respect, which is self-explanatory, is attached herewith.

Kindly take the above information on record.

Thanking you,

Yours truly,  
**For Pfizer Limited**

**Prajeet Nair**  
Company Secretary

Encl: A/a



## **STATEMENT FROM PFIZER LTD**

Pfizer Ltd. today announced that it has signed an agreement for the sale of four products marketed by its Global Established Products business in India. The brands Neko Soap, Sloans, Ferradol and Waterburys Compound will be divested to Piramal Enterprises Limited, for a consideration of Rs. 110 Crores, subject to adjustments for inventory on closing. The closure of this transaction is subject to obtaining requisite regulatory approvals and fulfilment of certain conditions by the parties.

“Pfizer’s portfolio includes medicines, vaccines and well-known consumer health care brands. This enables us to serve patients and physicians through a wide range of products in therapy areas most vital to public health. Our focus will remain on building and strengthening our presence in these segments. Nine of our top 10 brands are ranked number one in their respective categories and we will also continue to build on these ‘power brands,” said S. Sridhar, Managing Director of Pfizer Ltd.

“In line with our strategy – a commitment to the core business, active promotion of new and innovative products in key therapeutic areas and growth of power brands – we have decided to divest these four non-core products to Piramal Enterprises Ltd.”

### **About Pfizer Limited:**

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading Biopharmaceutical Company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 60 years in India, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at [www.pfizerindia.com](http://www.pfizerindia.com)

### **Disclaimer**

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries where such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advise may be obtained and necessary due diligence, investigation etc. may be done at your end.

For more information, please contact:

Saritha R Hajare  
Head – external Communications  
Pfizer Ltd  
Mobile no: +91 9619990917  
Email: Saritha.R.Hajare@pfizer.com